A single agent-combination hybrid phase I, dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous AVE0005 [aflibercept] administered every 2 weeks in combination with oral S-1 in patients with advanced solid malignancies.

Trial Profile

A single agent-combination hybrid phase I, dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous AVE0005 [aflibercept] administered every 2 weeks in combination with oral S-1 in patients with advanced solid malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2011

At a glance

  • Drugs Aflibercept; Gimeracil/oteracil/tegafur
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jan 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
    • 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Planned end date changed from Nov 2010 to Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top